Please provide your email address to receive an email when new articles are posted on . Treatment with biologic injections may lead to serious complications, such as infections requiring multiple ...

CAMBRIDGE, MA – Sept. 11, 2009 – Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon ...

The phase 3 IRAKLIA trial showed isatuximab's OBDS matches IV efficacy and pharmacokinetics, with fewer injection-site reactions. Subcutaneous isatuximab demonstrated a 71.1% objective response rate, ...

This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in ...

Aug. 9 (UPI) --The U.S. Food and Drug Administration on Friday announced the approval of the first nasal spray for treatment of anaphylaxis, a life-threatening allergic reaction. The epinephrine nasal ...

We could be nearing a cure for those nasty spring allergies — and even allergic reactions altogether. A decades-old asthma medication called omalizumab, which is sold as Xolair, has shown that it can ...